Inhibition of human exocrine pancreatic secretion by the long‐acting somatostatin analogue octreotide (SMS 201‐995)

Abstract

The new long-acting somatostatin analogue octreotide was investigated for its influence on segretatagogue-stimulated human exocrine pancreatic secretion. Eighteen healthy volunteers participated in the study. During duodenal intubation with a background stimulation of either secretin 1 U. kg/h or secretin 1 U. kg/h + ceruletide, 120 ng. kg/h, octreotide was infused at doses of 5, 20 and 80 pg/h in a placebo-controlled randomized double-blind crossover trial. Duodenal juice samples were collected in 10-min intervals, and amylase, trypsin, chymotrypsin, and bicarbonate were measured in the individual fractions. 59%, trypsin between 28 and 72%, chymotrypsin between 55 and 70%, and bicarbonate between 0 and 31 % with 5, 20 and 80 pg/h octreotide.During secretin and ceruletide stimulation, amylase was significantly inhibited by 84%, 789'0, 819'0, trypsin by 76%, 55 %, 52%, chymotrypsin by 77%, 55 %, 60%, and bicarbonate by 25 %, XI%, 19% with 5,2O, and 80pg/h octreotide, respectively (all decreases P < 0.05).During secretin stimulation, amylase was inhibited between 4 1 and Correspondence to : Professor Dr med. P. Malfertheiner, Universitat Ulm, Abteilung Innere Medizin 11,

Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management

“…Somatostatin analogues are an effective treatment option for patients with well‐established dumping syndrome who fail to respond to and/or do not tolerate initial dietary modification and acarbose treatment. Somatostatin analogues target various steps in the pathophysiology of dumping syndrome, including delaying gastric emptying, delaying transit through the small intestine, inhibiting the release of GI hormones, inhibiting insulin secretion and inhibiting postprandial vasodilation . Somatostatin inhibition of GLP‐1 secretion is mediated via activation of the somatostatin receptor subtype (sst) 5, with a lesser effect through sst2 .…”

Efficacy of the prophylactic use of octreotide for the prevention of complications after pancreatic resection

“…[12] It can powerfully inhibit basal and stimulated exocrine pancreatic secretion, making it more advantageous for clinical applications. [13] Octreotide has been recognized as one of the somatostatin analogs used in the prevention of PF after resection. [14] However, some different results have also been obtained.…”

A Novel Method for Pain Relief in Chronic Pancreatitis: an Old Drug in a New Pack: a Controlled Study

“…One more option for pain in CP is octreotide, an analogue of sandostatin [22]. This longer-acting octreotide was confirmed to be a potent inhibitor of stimulated human exocrine pancreatic secretion [23,24], thereby reducing pancreatic duct hypertension due to outflow obstruction and inhibiting pancreatic secretion thus reducing pain in CP [1]. It is the same mechanism as HDO.…”